trending Market Intelligence /marketintelligence/en/news-insights/trending/CNq6-eX2xeY8MxJeTzDquQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA grants clearance, waiver to Quidel's flu-detection test

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

US FDA grants clearance, waiver to Quidel's flu-detection test

The U.S. FDA granted a 510(k) clearance and a clinical laboratory improvements amendments waiver to Quidel Corp.'s Sofia Influenza A+B Fluorescent Immunoassay.

The regulator granted the clearance for the immunoassay to be used with the Sofia 2 Fluorescent Immunoassay Analyzer for quick differential detection of influenza types A and B from direct nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash specimens and nasopharyngeal swab and nasopharyngeal aspirate/wash specimens in transport media from symptomatic patients.

The Sofia Influenza A+B assay has improved lateral flow and immunofluorescence technologies to provide better clinical sensitivity for influenza A or B infections.